United Therapeutics Corporation Common Stock (NASDAQ: UTHR) last traded at $550.10, up 0.17% on the session. The quote above updates while this page is open; the figures below are drawn from United Therapeutics Corporation Common Stock’s own filings and are restated only when a new one is published.
United Therapeutics Corporation Common Stock trades on NASDAQ under the ticker UTHR. Its market capitalisation is $23.59 billion.
Valuation measures for United Therapeutics Corporation Common Stock, derived from the latest quote and its most recent SEC filing.
| Market cap | $23.59B |
|---|---|
| Enterprise value | $22.61B |
| P/E ratio | 19.71 |
| Price / sales | 7.48 |
| Price / book | 3.69 |
| Beta |
| 0.23 |
Trailing-twelve-month figures tagged in United Therapeutics Corporation Common Stock's XBRL filings with the SEC.
| Revenue (TTM) | $3.15B |
|---|---|
| Net income (TTM) | $1.31B |
| EPS (TTM) | $27.91 |
| Gross margin | 86.14% |
| Operating margin | 44.44% |
| Return on equity | 20.48% |
| Cash | $1.80B |
Range and volume for UTHR over the past 52 weeks.
| 52-week high | $609.35 |
|---|---|
| 52-week low | $409.07 |
| Volume | 422.9K |
| Average volume | 672.9K |
| Previous close | $549.16 |
Invest a chosen dollar amount in United Therapeutics Corporation Common Stock with fractional shares.
Start investingCreate an account
Investing involves risk, including possible loss of principal. Nothing here is investment advice or a recommendation to buy or sell UTHR.
A dash means FurlPay does not have that figure, not that it is zero. Nothing on this page is investment advice or a recommendation to buy or sell any security. Figures are provided for information only and may be delayed or restated.